摘要
间变性淋巴瘤激酶(ALK)融合是非小细胞肺癌(NSCLC)重要的驱动基因之一。ALK酪氨酸激酶抑制剂(ALK-TKI)对ALK融合基因阳性NSCLC患者有显著疗效。截至2023年6月27日,克唑替尼、塞瑞替尼、阿来替尼、恩沙替尼、布格替尼、洛拉替尼和伊鲁阿克等共7种ALK-TKI被中国国家药品监督管理局(NMPA)批准上市(按照获得NMPA批准上市时间排序),为ALK融合基因阳性晚期NSCLC患者提供了针对性的治疗选择。为规范ALK-TKI的使用,中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科学分会组织专家编写了《间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗晚期非小细胞肺癌中国专家建议(2024版)》。本专家建议从ALK融合基因检测、ALK-TKI靶向治疗、ALK-TKI不良反应管理以及治疗后患者随诊等4个方面给出推荐意见,为中国ALK融合基因阳性晚期NSCLC患者的规范治疗提供参考。
Anaplastic lymphoma kinase(ALK)fusion represents one of pivotal driver genes within the realm of non-small cell lung cancer(NSCLC).ALK-tyrosine kinase inhibitors(ALK-TKI)have demonstrated remarkable therapeutic efficacy for patients afflicted with ALK-positive NSCLC.As of June 27,2023,seven ALK-TKI,including crizotinib,ceritinib,alectinib,ensartinib,brigatinib,lorlatinib,and iruplinalkib,have garnered approval from the China National Medical Products Administration(NMPA)(ranking according to the approval time for marketing by NMPA),providing individualized treatment modalities for ALK-positive NSCLC patients.To standardize the application of ALK-TKI,the Chinese Association for Clinical Oncologists and the Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care has organized experts to compile the"China expert recommendations on anaplastic lymphoma kinase-tyrosine kinase inhibitors treatment for advanced non-small cell lung cancer(2024 edition)".This treatment expert recommendation provides recommendations in four aspects,encompassing ALK fusion testing,ALK-TKI targeted therapy,ALK-TKI adverse events management,and patient post-treatment follow-up,thus serving as a valuable reference for the standardized treatment of Chinese advanced ALK fusion-positive NSCLC.
作者
中国医师协会肿瘤医师分会
中国医疗保健国际交流促进会肿瘤内科学分会
石远凯
郝学志
汪麟
韩晓红
王征
朱豪华
谢同济
陈馨蕊
谢祖成
Chinese Association for Clinical Oncologists;Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care;Shi Yuankai(不详;Department of Medical Oncology,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2024年第7期473-485,共13页
National Medical Journal of China
基金
国家“重大新药创制”科技重大专项(2017ZX09304015)
关键词
癌
非小细胞肺
间变性淋巴瘤激酶
酪氨酸激酶抑制剂
专家建议
Carcinoma,non-small-cell lung
Anaplastic lymphoma kinase
Tyrosine kinase inhibitor
Experts recommendations
作者简介
通信作者:石远凯,国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院内科,抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021,Email:syuankai@cicams.ac.cn
